Mutations induced by α-hydroxytamoxifen in the lacI and cII genes of big blue transgenic rats

Carcinogenesis

Volumn 23, Issue 10, 2002, Pages 1751-1757

  Chen, Tao ^a   Da Costa, Goncialo Gamboa ^b   Marques, M Matilde ^b   Shelton, Sharon D ^a   Beland, Frederick A ^a   Manjanatha, Mugimane G ^a  

^a NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH   (United States)

^b INSTITUTO SUPERIOR TÉCNICO   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; AMINO ACID; CYTOSINE; DRUG METABOLITE; GUANINE; HYDROXYTAMOXIFEN; LIVER PROTEIN; TAMOXIFEN; THYMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; INDUCED MUTATION; LIVER CARCINOGENESIS; LIVER TUMOR; MUTATION RATE; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; PRIORITY JOURNAL; RAT; RAT STRAIN; TRANSGENIC ANIMAL;

AMINO ACID SUBSTITUTION; ANIMALS; ANIMALS, GENETICALLY MODIFIED; BACTERIAL PROTEINS; BASE SEQUENCE; ESCHERICHIA COLI PROTEINS; FRAMESHIFT MUTATION; GENE EXPRESSION REGULATION; MUTAGENESIS, SITE-DIRECTED; MUTAGENS; RATS; REPRESSOR PROTEINS; TAMOXIFEN;

EID: 0036798839     PISSN: 01433334     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Early Breast Cancer Trialists' Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet, 351, 1451-1467.
2. Fisher, B., Costantino, J.P., Wickerham, D.L., et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst., 90, 1371-1388.
3. Stearns, V. and Gelmann, E.P. (1998) Does tamoxifen cause cancer in humans? J. Clin. Oncol., 16, 779-792.
4. Hard, G.C., Williams, G.M. and Iatropoulos, M.J. (1993) Tamoxifen and liver cancer. Lancet, 342, 444-445.
5. Williains, G.M., Iatropoulos, M.J., Djordjevic, M.V. and Kaltenberg, O.P. (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis, 14, 315-317.
6. Mäntylä, E., Nieminen, L. and Karlsson, S. (1995) Endometrial cancer induction by tamoxifen in the rat. Eur J. Cancer, 31A (Suppl. 5), S14.
7. Mäntylä, E.T.E., Karlsson, S.H. and Nieminen, L.S. (1996) Induction of endometrial cancer by tamoxifen in the rat. In: Li,J.J., Li,S.A., Gustafsson, J.Å., Nandi S. and Sekely, L.I. (eds.) Hormonal Carcinogenesis. IL Proceedings of the Second International Symposium, Springer, New York, pp. 442-445.
8. Osborne, M.R., Hewer, A., Hardcastle, I.R., Carmichael, P.L. and Phillips, D.H. (1996) Identification of the major tamoxifen-deoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res., 56, 66-71.
9. Davies, R., Oreffo, V.I.C., Martin, E.A., Festing, M.F.W., White, I.N.H., Smith, L.L. and Styles, J.A. (1997) Tamoxifen causes gene mutations in the livers of lambda/lacI transgenic rats. Cancer Res., 57, 1288-1293.
10. White, I.N.H., Carthew, P., Davies, R., Styles, J., Brown, K., Brown, J.E., Smith, L.L. and Martin, E.A. (2001) Short-term dosing of α-hydroxytamoxifen results in DNA damage but does not lead to liver tumours in female Wistar/Han rats. Carcinogenesis, 22, 553-557.
11. Gamboa da Costa, G., Manjanatha, M.G., Marques, M.M. and Beland, F.A. (2002) Induction of lacI mutations in Big Blue rats treated with tamoxifen and α-hydroxytamoxifen. Cancer Lett., 176, 37-45.
12. Gamboa da Costa, G., McDaniel-Hamilton, L.P., Heflich, R.H., Marques, M.M. and Beland, F.A. (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis, 22, 1307-1315.
13. Schild, L.J., Divi, R.L. and Poirier, M.C. (2002) Formation of tamoxifen-DNA adducts in organs of monkeys dosed orally with tamoxifen for 30 days. Environ. Mol. Mutagen., 39 (Suppl. 33), 56.
14. Beland, F.A., Churchwell, M.I., Doerge, D.R., Malejka-Giganti, D., Zhang, X., Divi, R.L., Poirier, M.C., Gamboa da Costa, G. and Marques, M.M. (2002) High performance liquid chromatography electrospray ionization mass spectrometry analysis of tamoxifen DNA adducts in rats, monkeys and humans. Proc. Am. Assoc. Cancer Res., 43, 343.
15. Phillips, D.H. (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis, 22, 839-849.
16. Davis, W., Venitt, S. and Phillips, D.H. (1998) The metabolic activation of tamoxifen and a-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis, 19, 861-866.
17. Shibutani, S., Dasaradhi, L., Terashima, I., Banoglu, E. and Duffel, M.W. (1998) α-Hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res., 58, 647-653.
18. Glatt, H., Bartsch, I., Christoph, S., Coughtrie, M.W.H., Falany, C.N., Hagen, M., Landsiedel, R., Pabel, U., Phillips, D.H., Seidel, A. and Yamazoe, Y. (1998) Sulfotransferase-mediated activation of mutagens studied using heterologous expression systems. Chem.-Biol. Interact., 109, 195-219.
19. White, I.N.H. (1999) The tamoxifen dilemma. Carcinogenesis, 20, 1153-1160.
20. Osborne, M.R., Hardcastle, I.R. and Phillips, D.H. (1997) Minor products of reaction of DNA with α-acetoxytamoxifen. Carcinogenesis, 18, 539-543.
21. Tucker, M..J., Adam, H.K. and Patterson, J.S. (1984) Tamoxifen. In: Laurence, D.R., McLean, A.E.M. and Weatherall, M. (eds.) Safety Testing of New Drugs. Academic Press, New York, pp. 125-161.
22. White, I.N.H., de Matteis, R, Davies, A., Smith, L.L., Crofton-Sleigh, C., Venitt, S., Hewer, A. and Phillips, D.H. (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis, 13, 2197-2203.
23. Styles, J.A., Davies, A., Lim, C.K., de Matteis, F., Stanley, L.A., White, I.N.H., Yuan, Z.-X. and Smith, L.L. (1994) Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis, 15, 5-9.
24. Davies, R., Oreffo, V.I.C., Bayliss, S., Dinh, P.-A., Lilley, K.S., White, I.N.H., Smith, L.L. and Styles, J.A. (1996) Mutational spectra of tamoxifen-induced mutations in the livers of lacI transgenic rats. Environ. Mol. Mutagen., 28, 430-433.
25. Davies, R., Gant, T.W., Smith, L.L. and Styles, J.A. (1999) Tamoxifen induces G:C → T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5′-CpG-3′ dinucleotide sequences as found in the lacI transgene. Carcinogenesis, 20, 1351-1356.
26. Foster, A.B., Jarman, M., Leung, O.-T., McCague, R., Leclercq, G. and Devleeschouwer, N. (1985) Hydroxy derivatives of tamoxifen. J. Med. Chem., 28, 1491-1497.
27. Chen, T., Aidoo, A., Manjanatha, M.G., Mittelstaedt, R.A., Shelton, S.D., Lyn-Cook, L.E., Casciano, D.A. and Heflich, R.H. (1998) Comparison of mutant frequencies and types of mutations induced by thiotepa in the endogenous Hprt gene and transgenic lacI gene of Big Blue® rats. Mutat. Res., 403, 199-214.
28. Manjanatha, M.G., Shelton, S.D., Culp,S. J., Blankenship, L.R. and Casciano, D.A. (2000) DNA adduct formation and molecular analysis of in vivo lacI mutations in the mammary tissue of Big Blue® rats treated with 7,12-dimethylbenz[a]anthracene. Carcinogenesis, 21, 265-273.
29. Manjanatha, M.G., Chen, J.B., Shaddock, J.G., Jr., Harris, A.J., Shelton, S.D. and Casciano, D.A. (1996) Molecular analysis of lacl mutations in Rat2™ cells exposed to 7,12-dimethylbenz[a]anthracene: evidence for DNA sequence and DNA strand biases for mutation. Mutat. Res., 372, 53-64.
30. Cariello, N.F. (1994) Software for the analysis of mutations at the human hprt gene. Mutat. Res., 312, 173-185.
31. Adams, W.T. and Skopek, T.R. (1987) Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol., 194, 391-396.
32. Farabaugh, P.J., Schmeissner, U., Hofer, M. and Miller, J.H. (1978) Genetic studies of the lac repressor. VII. On the molecular nature of spontaneous hotspots in the lacI gene of Escherichia coli. J. Mol. Biol., 126, 847-863.
33. Chen, T., Mittelstaedt, R.A., Shelton, S.D., Dass, S.B., Manjanatha, M.G., Casciano,D.A. and Heflich,R.H. (2001) Gene- and tissue-specificity of mutation in Big Blue® rats treated with the hepatocarcinogen N-hydroxy-2-acetylaminofluorene. Environ. Mol. Mutagen., 37, 203-214.
34. Harbach, P.R., Zimmer, D.M., Filipunas, A.L., Mattes, W.B. and Aaron, C.S. (1999) Spontaneous mutation spectrum at the lambda cII locus in liver, lung, and spleen tissue of Big Blue® transgenic mice. Environ. Mol. Mutagen., 33, 132-143.
35. Skopek, T.R., Kort, K.L., Marino, D.R., Mittal, L.V., Umbenhauer, D.R., Laws, G.M. and Adams, S.P. (1996) Mutagenic response of the endogenous hprt gene and lacI transgene in benzo[a]pyrene-treated Big Blue™ B6C3F1 mice. Environ. Mol. Mutagen., 28, 376-384.
36. Jakubczak, J.L., Merlino, G., French, J.E., Muller, W.J., Paul, B., Adhya, S. and Garges, S. (1996) Analysis of genetic instability during mammary tumor progression using a novel selection-based assay for in vivo mutations in a bacteriophage λ transgene target. Proc. Natl Acad. Sci. USA, 93, 9073-9078.